Author:
Zhou Ming,Zhao Yuhua,Ding Yan,Liu Hao,Liu Zixing,Fodstad Oystein,Riker Adam I,Kamarajugadda Sushama,Lu Jianrong,Owen Laurie B,Ledoux Susan P,Tan Ming
Abstract
AbstractBackgroundTaxol is one of the most effective chemotherapeutic agents for the treatment of patients with breast cancer. Despite impressive clinical responses initially, the majority of patients eventually develop resistance to Taxol. Lactate dehydrogenase-A (LDH-A) is one of the predominant isoforms of LDH expressed in breast tissue, which controls the conversion of pyruvate to lactate and plays an important role in glucose metabolism. In this study we investigated the role of LDH-A in mediating Taxol resistance in human breast cancer cells.ResultsTaxol-resistant subclones, derived from the cancer cell line MDA-MB-435, sustained continuous growth in high concentrations of Taxol while the Taxol-sensitive cells could not. The increased expression and activity of LDH-A were detected in Taxol-resistant cells when compared with their parental cells. The downregulation of LDH-A by siRNA significantly increased the sensitivity of Taxol-resistant cells to Taxol. A higher sensitivity to the specific LDH inhibitor, oxamate, was found in the Taxol-resistant cells. Furthermore, treating cells with the combination of Taxol and oxamate showed a synergistical inhibitory effect on Taxol-resistant breast cancer cells by promoting apoptosis in these cells.ConclusionLDH-A plays an important role in Taxol resistance and inhibition of LDH-A re-sensitizes Taxol-resistant cells to Taxol. This supports that Warburg effect is a property of Taxol resistant cancer cells and may play an important role in the development of Taxol resistance. To our knowledge, this is the first report showing that the increased expression of LDH-A plays an important role in Taxol resistance of human breast cancer cells. This study provides valuable information for the future development and use of targeted therapies, such as oxamate, for the treatment of patients with Taxol-resistant breast cancer.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology,Molecular Medicine
Reference32 articles.
1. Henley D, Isbill M, Fernando R, Foster JS, Wimalasena J: Paclitaxel induced apoptosis in breast cancer cells requires cell cycle transit but not Cdc2 activity. Cancer Chemother Pharmacol. 2007, 59 (2): 235-249. 10.1007/s00280-006-0262-1
2. Tan M, Yu D: Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. Adv Exp Med Biol. 2007, 608: 119-129. full_text
3. Frankel Andrea, Buckman Robert, Kerbel Robert: Abrogation of Taxol- induced G2-M Arrest and Apoptosis in Human Ovarian Cancer Cells Grown as Multicellular Tumor Spheroids. Cancer Res. 1997, 57: 2388-2293.
4. Chen LP, Cai SM, Fan JX, Li ZT: PEBA Regimen (Cisplatin, Etoposide, Bleomycin, and Adriamycin) in the Treatment of Drug-Resistant Choriocarcinoma. Gynecologic Oncology. 2002, 56 (2): 231-234.
5. Donnenberg Vera, Donnenberg Albert: Multiple Drug Resistance in Cancer Revisited: The Cancer Stem Cell Hypothesis. J Clin Pharmacol. 2005, 45: 872-877. 10.1177/0091270005276905
Cited by
314 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献